Three of MSAA’s free resources were recognized by the 2018 Digital Health Awards for their excellence in digital communication.
Read News ArticleCategory: Latest News
MRI Access Fund Expanded to Help Members of the Multiple Sclerosis Community
The MRI Access Fund assists with the payment of cranial (brain) and c-spine MRI scans for qualified individuals who have no medical insurance or cannot afford their insurance costs. The exam must be required by a physician to help determine a diagnosis of multiple sclerosis or evaluate current MS disease progression.
Read News ArticleMSAA’s Blog and Mobile Phone App Recognized by Healthline
The Multiple Sclerosis Association of America (MSAA) is pleased to announce that our blog, MS Conversations, has been named one of the Best Multiple Sclerosis Blogs for the fourth consecutive year by Healthline!
Read News ArticleFDA Approves Gilenya® for Pediatric MS
On May 11, 2018, Novartis announced that Gilenya® (fingolimod) was approved by the United States Food and Drug Administration (FDA) for the treatment of children and adolescents, ages 10 through 17, with relapsing multiple sclerosis (MS). This is the first disease-modifying therapy (DMT) to be approved for this form of the disease in this age […]
Read News ArticleFDA Helping with Zinbryta® Withdrawal
As a follow-up to MSAA’s online article, “Zinbryta® Withdrawn from Marketplace,” MSAA is alerting individuals taking Zinbryta® (daclizumab) to additional information on the withdrawal. On March 14, 2018, the United States Food and Drug Administration (FDA) issued a press release to assist with the withdrawal of Zinbryta from the market in the United States. They […]
Read News ArticleZinbryta® Withdrawn from Marketplace
On March 2, 2018, Biogen and AbbVie announced the voluntary withdrawal of their MS medication, Zinbryta® (daclizumab), due to new safety concerns. Eight cases of inflammatory encephalitis and meningoencephalitis – both forms of brain inflammation – have been reported in two European countries. According to Reuters, seven cases of these serious brain disorders occurred in […]
Read News Article
MSAA Draws Attention to Multiple Sclerosis Progression during MS Awareness Month
The organization will host a series of activities and events focused on providing education and raising awareness about multiple sclerosis during the month of March March is officially recognized as MS Awareness Month, and the Multiple Sclerosis Association of America (MSAA) is focusing their 2018 MS Awareness Month campaign on Understanding MS progression, with specific […]
Read News ArticleFDA Approves Three-Times Weekly Dose of Glatopa®
Sandoz, a Novartis division, announced today that the United States Food and Drug Administration (FDA) approved Glatopa® (glatiramer acetate injection) at a three-times weekly 40-mg dose. This generic version of Copaxone®, a disease-modifying therapy (DMT) approved for the treatment of relapsing forms of multiple sclerosis (MS), was initially approved at a 20-mg daily dose. Both […]
Read News ArticleBloomberg Senior Executive Editor Among Honorees at National Annual Benefit
John McCorry, Senior Executive Editor for the Americas at Bloomberg News; Dorothea Pfohl, Founding Member of IOMSN; and the Knights of Columbus Santa Maria Council #1443 will be recognized by MSAA The Multiple Sclerosis Association of America (MSAA) is proud to announce their distinguished honorees for the 2018 Improving Lives Benefit scheduled for Thursday, March […]
Read News ArticleFDA Grants Gilenya® Breakthrough Therapy Designation for Pediatric MS
On December 18, 2017, Novartis announced that Gilenya® (fingolimod) was granted breakthrough therapy designation by the United States Food and Drug Administration (FDA) for the treatment of children and adolescents ages 10 years or older with relapsing multiple sclerosis (MS). Known as “pediatric MS,” nearly all (98 percent) of those diagnosed experience the relapsing form […]
Read News Article